Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Here's the second talk from our recent webinar, partnering with LUNGevity Foundation to cover the ASCO Highlights in Lung Cancer, and this talk followed after the presentation by Dr. Mary Pinder on highlights in SCLC, early stage NSCLC, and mesothelioma and covered developments in advanced NSCLC. Dr. Nasser Hanna, an international leader in the field from Indiana University, summarized the most important new data in this arena.
Below you'll find links to the audio and video versions of the podcast, as well as the transcript and figures from his talk.
[powerpress]
hanna-asco-2011-highlights-advanced-nsclc-audio-podcast
hanna-asco-2011-highlights-advanced-nsclc-transcript
hanna-asco-2011-highlights-advanced-nsclc-figures
The third and final podcast in this series will be the question and answer session, which will be out shortly.
As always, we welcome your questions and comments here. On behalf of GRACE and LUNGevity Foundation, we hope you find this webinar content helpful.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…